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 Biomarkers and the methods which are utilized to detect them are at the forefront of 
disease prevention, detection, and prognosis. To further the prostate cancer clinical detection 
modalities, quartz crystal microbalances with dissipation (QCM-D) were inoculated with a 
functional layer of antibodies to afford an immuno-specific biosensor capable of reporting 
frequency, dissipation, and viscoelasticity shifts indicative of changes in surface chemistry. 
Because serum protein binding occurs selectively at the antibody’s paratope and non-selectively 
at the QCM-D surface, multiple sensors were used simultaneously to isolate the frequency and 
dissipation shifts due exclusively to the antigen-antibody binding event. Early studies with 
fluorescein isothiocyanate (FITC) indicated that binding to its respective antibody yielded 
significantly positive frequency shifts in a dose-dependent fashion, contrary to the Sauerbrey 
model. The data, however, fits a time-dependent perturbation theory in which surface frequency 
changes during adsorption are due to both mass and stiffness changes. FITC was further used as 
a reference sensor to account for the non-specific binding of Bovine Serum Albumin (BSA) in a 
recombinant BSA solution and several solutions of fetal bovine serum (FBS). FBS was diluted to 
the same BSA concentration as a recombinant solution and experimentation showed no 
significant difference in detected frequency shift, despite a large difference in viscosity. These 
findings indicate that only recombinant protein is necessary when creating dose-response curves 
for calibrating an assay from this technique. Pure samples of FBS were also studied, and 
exhibited frequency shifts similar to a multiple of the prior FBS dilution factor. These proof of 
concept studies allowed for the simultaneous detection of PSA, alkaline phosphatase, and 
Simple-minded homolog 2 (SIM2) in human serum from patients with either recurrent or non-
recurrent prostate cancer. Repeated trials will allow for robust comparison between cohorts. 
© Christopher K. Giardina 2011  5 
© Christopher K. Giardina 2011  6 
BACKGROUND 
 
1. Prostate Cancer Biomarker Upregulation 
1.1 Prostate Carcinoma 
 One man in six will be diagnosed with prostate cancer at some time in his lifetime. In 
2009, prostate cancer was the most highly diagnosed male cancer, and was the leading cause of 
cancer-induced deaths after lung cancer. The American Cancer Society also predicts that 217,730 
new cases of prostate cancer will be diagnosed and 32,050 patients will die in the 2010 year 
alone.
1
 After radiation and chemotherapy, the risk of prostate cancer recurrence is always 
present. Currently, no such assay or standardized test exists which assesses the risk of 
recurrence. 
 
Figure 1: Prostate Cancer Cell Morphologies. As prostate cancer cells progress from benign to malignant, they 
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Although there are several tissue layers within the prostate, 99% of all prostate cancers 
are adenocarcinomas, arising from the glandular cells which secrete seminal fluid.
2
 Cells exhibit 
cancerous behavior when they acquire traits and defects in regulatory signaling pathways which 
ultimately augment cell homeostasis. These traits include self-sufficiency in growth signals, 
insensitivity to antigrowth signals, apoptosis-evading mechanisms, limitless reproductive 
potential, sustained angiogenesis, and tissue invasion and metastatic mechanisms.
3
 As these 
prostate glandular cells divide uncontrollably, the tissue layers undergo several morphological 
changes (Figure 1). 
 
1.2 Prostate Cancer Biomarkers and Recurrence 
The prostate‟s high level of interaction with systemic biological queues makes it a prime 
candidate for determining the stage of the cancer from a blood sample. Protein secretion and 
expression patterns are drastically different at different stages in the disease and are proposed to 
vary before and after radiation or chemotherapy (Figure 2). 
 
Figure 2: Biomarker Secretion Patterns. As prostate cancer cells progress from benign to malignant to aggressive, 
their behaviors and secretion patterns differ. However, little research has been conducted to infer recurrence. 
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With reference to prostate cancer, many markers have been shown to be elevated in 































 have all shown to have 
increased levels in either serum, urine, or tissue biopsy in human samples. In particular, Prostate-
Specific Antigen (PSA) is the gold standard and the only approved serum biomarker that the 
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Figure 3: Extracellular Serum Biomarkers. Biomarkers in this list have been shown to be significantly elevated when 
compared to non-cancerous equivalents. 
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The markers listed inFigure 3 exemplify several of the few markers tested on actual 
human samples. As tumor tissue becomes increasingly neoplasic, cell disorganization causes a 
vast number of the cells to lyse due to abnormal stress and strain on the plasma membrane of the 
cells.
2
 The tumor continues to grow in volume, the cells which rupture, and the entire cytosolic 
contents spill into the surrounding extracellular space.
13
 Although these chemicals are usually 
destroyed via serum proteases, macrophage activity, and renal clearance, increased vasculature 
due to abnormal angiogenesis permits these highly concentrated intracellular proteins to have 




 levels have been 
significantly differentiated in cancerous vs. non-cancerous serum.  
A Banyard et al. study reviews growth factors, cytokines, hormones, membrane 
receptors, proteases, actin-binding proteins, tumor-supressor genes, and intracellular signaling 
proteins which are either up- or down-regulated in human PC3, LNCaP and ARCaP prostate 
cancer cell lines in terms of both cell motility and metastasis.
16
 One study by Varambally et al. 
attempted to quantify both intracellular and extracellular proteins by analyzing tissue extracts 
from prostate organs at the time of radical prostatectomy.
14
 Although the literature presented in 
Figure 3 present an “all or nothing” approach to detecting prostate cancer, the Varambally et al. 
study detected clinically localized benign cancer (Figure 4) and metastatic cancer (Figure 5). 















Myosin VI Protein Biopsy + Verified in 8/9 studies 
14
 
BUB3 Protein Biopsy + Verified in 6/9 studies 
PSA Protein Biopsy + Verified in 5/9 studies 
Aurora Kinase A Protein Biopsy + Verified in 5/9 studies 
AMACR Protein Biopsy + Verified in 8/9 studies 
HSP60 Protein Biopsy + Verified in 6/9 studies 
CDK7 Protein Biopsy + Verified in 7/9 studies 
TPD52 Protein Biopsy + Verified in 6/9 studies 
Figure 4: Biomarkers for Presence of Prostate Cancer. These biomarkers were quantified from tissue extractions 
at the time of radical prostatectomy. This table depicts which markers are clinically useful in differentiating between 











Aurura Kinase A Protein Biopsy + Verified in 5/5 studies 
14
 
EZH2 Protein Biopsy + Verified in 5/5 studies 
Nucleoporin p62 Protein Biopsy + Verified in 4/5 studies 
LAP2 Protein Biopsy + Verified in 4/5 studies 
Ral A Protein Biopsy + Verified in 4/5 studies 
Ubc9 Protein Biopsy + Verified in 4/5 studies 
Exportin1 Protein Biopsy + Verified in 3/5 studies 
P16INK4A Protein Biopsy + Verified in 3/5 studies 
MSH2 Protein Biopsy + Verified in 3/5 studies 
Figure 5: Biomarkers for Aggressiveness of Prostate Cancer. These biomarkers were quantified from tissue 
extractions at the time of radical prostatectomy. This table depicts which markers are clinically useful in 
differentiating between localized, benign tissue and metastatic tissue. Source: 
14 
 
Despite these robust findings, the majority of the focus has been on detection of cancer 
(comparing non-cancerous samples with cancerous samples) and not testing for recurrence 
(comparing cancerous vs non-cancerous after chemical or radiation treatment). This is 
represented in Figure 6; most studies compare A and B, whereas few compare C and D. Serum 
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from patients with recurrence and serum with patients without recurrence will be assayed to 
determine the level of several biomarkers. Ideally, a discrepency between the recurrent and non-
recurrent samples will provide a useful tool in assessing risk of recurrence from a patient after 




Figure 6: Strategies for Cancer Detection. (A) represents non-cancerous levels, (B) represents the levels required 
for the detection of cancer, (C) represents a secondary threshold for detecting recurrence, and (D) represents a 
successful treatment with no recurrence. 
 
1.3 Serum Controls 
In any analysis of serum biomarkers, phrases such as “upregulated” and “downregulated” 
are relative values for comparison. Usually, the level of such a biomarker is quantified over time, 
such that changes in the biomarker are compared or normalized to some previous value. 
Unfortunately, identifying risk of recurrence for prostate cancer is extremely important 
immediately after chemotherapy will occur, at a single time from a single test. It would be naïve 
to compare serum levels to a “pooled average” of every person, because the “normal” level of 
markers in serum is different from person to person. A better method would be to normalize the 
level of a biomarker to some standard and use the patient as his own control. Alkaline 
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phosphatase (ALP), which retains blood pH, is a strong candidate because its concentrations 
remain relatively stable in the blood throughout a person‟s lifetime.
17
 Albumin, a protein 
involved in retaining serum oncotic pressure, is also relatively stable during a patient‟s lifetime 




Marker Use in Experiment 
PSA (Prostate-Specific Antigen) Gold Standard 
SIM2 (Simple-Minded Homolog 2) Biomarker of interest 
ALP (Alkaline Phosphatase) Serum Control 
 
Figure 7: Selected Biomarkers for This Study. PSA is a gold standard, ALP will be a serum control, and SIM2 
will be of specific interest. 
 
 The three biomarkers chosen for this specific study (Figure 7) were Prostate-Specific 
Antigen (PSA), Alkaline Phosphatase (ALP), and Single-Minded Homolog 2 (SIM2). PSA has 
long been utilized as a gold standard, ALP will represent a serum control, and SIM2 will be an 
experimental marker. It is expected that PSA and SIM2 will be higher in the patients with 
recurrence, and that the ALP will show no significant difference between groups. Relative levels 
will be calculated as: 
 
                
                                
                             
                                    
 
in which levels are reported as a fraction of some patient-specific serum control. Ideally, the 
levels of reference biomarker (alkaline phosphatase) will have a much lower range of variance 
than the experimental biomarkers themselves. The final step in the design is selection of the 
protocol to detect the markers.  
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2. Acoustic Wave Immunosensors 
2.1 PiezoelectricAcoustic Waves 
Piezoelectric materials directly convert mechanical stimuli into electrical stimuli, and 
vice versa. They are the link between mechanical and electrical phenomena and as such, a simple 
voltmeter can track changes in mechanical stimuli on the surface of the material. Mechanical 
signals in piezoelectric materials propagate either on the surface or through the material itself. 
Surface acoustic waves (SAWs) generate mechanical waves in the crystal parallel to the surface 
whereas bulk acoustic waves (BAWs) are designed to generate oscillations perpendicular to the 
surface of the material (Figure8). Such oscillations are recorded as voltages over time. 
 
 
Figure 8:  Bulk and Surface Acoustic Waves. Mechanically induced waves in piezoelectric materials convert 
physical crystal stretching into electric signals. (A) Bulk acoustic waves (BAW) generate mechanical waves into the 
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The voltage-varying signal can be explored using a real-time discrete Fourier transform 
(Equation 2) to decipher the frequencies of the signal over preselected time intervals: 
     ∑     
 
    
                                                                
 The change in frequency of the resonator indicates a change in any of the multitude of surface 
boundary conditions, such as mass loading or shear stress, with great specificity.  
SAW devices are quite large, must be cut from a perfect crystal, and are inherently 
difficult to integrate into microchips. Thus, BAW devices have become a better candidate for 
potential biosensors.
20
 The resonant frequency of a BAW device is described by:  
   
   
  
                                                                        
Where va is the acoustic velocity, N is the mode number, and d is the film thickness. In 1959, 
Sauerbrey described the relationship between the mass loading on the sensor itself (∆m) with the 
observed electrical frequency change (∆f) 
21
: 
   
   
   
 √    
                                                                              
Where Δƒ is the change in frequency, ƒo is the unloaded resonance frequency, Δm is the change 
in mass loading at the surface, A is the area of operation, q is the crystal mass density and q is 
the crystal elastic stiffness. In addition, the equation governing liquid interactions with a surface 
was described in 1985
22
: 




     
                                                                    
Where f0 is again resonant frequency, η and ρ are viscosity and absolute density of the solution, 
and µq and ρq are shear stiffness and density of the BAW resonator. 
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2.2 Quantum Crystal Microbalance with Dissipation (QCM-D) Biosensor 
The Quartz Crystal Microbalance (QCM), the most commonly used BAW sensor used 
today
20
, was first described by Jacques and Pierre Curie in 1880.
23
 The QCM is an ideal BAW 
sensor with air interface. The QCM, however, isn‟t an ideal biosensor due to its low frequency of 
operation (between 5 and 35 MHz).
20
 Higher device operating frequencies lead to higher acoustic 
detection sensitivity.
24
 A film bulk acoustic resonator (FBAR) contains layers of semiconducting 
film upon a standard BAW device platform to increase the internal resonant frequency well into 




Figure 9:  BAW Sensor and FBAR. Examples of QCM technology. (A) A standard QCM with a low operating 
resonant frequency. (B) A standard FBAR. Alternating film layers upon a QCM increase the internal resonant 





 The resonator becomes a biosensor when the surface material becomes inoculated with a 
layer of antibodies specific to a target antigen (Figure 10). The QCM was used for the first time 
as an immunosensor in 1976.
26
 Binding events in the biolayer cause changes in the surface 
boundary conditions resulting in a change of the resonance frequency. Instead of measuring 
elusiveand indistinguishable changes at the surface, the resonator will now specifically measure 
immunobinding events in which the antibodies bind to target antigens in a liquid solution. 
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Figure 10:  QCM Biosensor. Antibodies inoculated to the surface of the QCM are used to detect binding events 
indicative of a target molecule. (a) The QCM biosensor vibrates as an internal resonant frequency. (b) Once target 






The process of using antibodies ensures that the only mass loading events associated with 
the device are antigen immunoevents. However, extraction of mass data from observed 
frequency recordings can no longer be performed with the standard equations presented in 
Equations 2 to 5 because the biofilm adds additional physical characteristics which need to be 
mathematically addressed (Figure 11). 
 
 
Figure 11:  QCM Biosensor BAW model. Antibodies upon the hf region introduce another mathematical boundary 
which needs to be addressed in the Sauerbrey model before mass calculations can be made. Source: 
27
. 
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In order to mathematically incorporate the biofilm layer, Hunt et al. developed a partial 
differential equation which incorporates the stiffness change of the QCM as a result of an 




   
  
    
    
 √    
 {   [   
  
   
]   [




   
 
   
  
]}                       
where the subscript µ denotes the unperturbed field condition, f denotes the immobilized chemi-
specific film,  is the radian frequency, VS is the velocity of the shear acoustic wave, and hƒ is 
the height of the immobilized surface.  Assuming that ∆ρ, ∆µ, and ∆ω do not change with time, 
Hunt‟s equation (6) reduces to: 
   
   
   
 √    
[   
  
   
]                                                                  
where µq and ρq are mass constants and mass loading is expressed as         .This equation 
is essentially the Sauerbrey Equation (4) in which the mass change ∆m is expanded to include 
mechanical stiffness of the antibody layer. Individual sensors (Figure 12A) can be combined in 
series on a single chip (Figure 12B) to simultaneously infer 8 biomarker levels from a sample.  
 
Figure 12:  Individual Sensor and AcµRayMultisensor. Initial testing of individual biomolecules will take place 
on (A) QCM sensor pads.  Eventually, once candidate biomarkers are validated, up to 8 markers can simultaneously 







© Christopher K. Giardina 2011  18 
RESEARCH CONDUCTED 
1. Biosensor Design 
The detection of specific serum proteins is the foundation for all biomarker analyses. 
Concerning cancer, biomarkers are often utilized for both diagnosis and prognosis of disease 
during risk assessment, screening, classification, tumor stage, tumor grade, of even risk of 
recurrence.
30
 Inherent in this analysis is the sensitivity and selectivity of the method to detect the 
biomarker. A gold-standard biomarker detection method in clinical settings is the clinical 
ELISA
31
, which is relatively tedious, expensive, and must be performed by trained personnel. In 
1880, Quartz Crystal Microbalances (QCMs) were first described
23
 and have since been used as 
chemical sensors due to their unique piezoelectric ability to translate changes in surface 
chemistry into electric signals. In 1959, it was determined that deposition mass on the QCM 
surface can be inferred from the drop in QCM resonant frequency using the Sauerbrey 
equation.
21
 The resonator becomes a biosensor when the surface material becomes inoculated 
with a layer of antibodies specific to a target antigen. Ideally, the process of using antibodies 
ensures that the only mass loading events detected by the QCM resonator are antibody-antigen 
immunobinding events. In 1972, the QCM was first used as an immunosensor
26
 and has since 













. An additional 
aid in this detection is the QCM with dissipation (QCM-D), which allows for the simultaneous 
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Some organic molecules, such as alkanethiols, have the capacity to spontaneously 
chemisorb onto the gold QCM surface. Exploiting this technique allows for the formation of a 
nearly-perpendicular self-assembled monolayer (SAM) of carbon chains, to which antibodies can 
adhere.
41
 Once the selective biofilm is created, the QCM-D sensor can be presented with antigen-
containing solutions for electric detection. When the antigen does not naturally chemisorb to the 
gold QCM surface, it can be assumed that the entire electric frequency shift recorded from the 
QCM-D is due to an antibody-antigen binding event at the antibody‟s paratope. Fluorescein 
isothiocyanate (FITC) is an example of such a compound. However, if the antigen chemisorbs 
onto the gold surface spontaneously, the measured frequency shift of the sensor incorporates 
both specific binding at the antibody‟s paratope and the disorderly nonspecific binding onto the 
gold surface itself (Equation 8).  
 
                                                                                    
 
 
This problem of simultaneous detection of specific and non-specific binding is alleviated 
with the use of a reference sensor: a second QCM-D sensor designed to detect a chemical which 
isn‟t in the antigen-containing solution (Figure 13). When both reference sensor and target sensor 
are exposed to the same antigen-containing solution, it is assumed that the nonspecific binding in 
each sensor is equal. Thus, the measurements from the reference sensor represents an 
accumulation of all non-specific binding on the target sensor and can be subtracted from the 
frequency shift of the target sensor to extrapolate the frequency shift due solely to 
theimmunobinding event (Equation 9). This approach also controls for the nonspecific binding of 
other molecules onto the QCM surface, which is useful when detecting a target antigen in a 
solution of complex biological media such as cell suspensions or serum. 
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In order to detect a specific protein in a blood sample, for example, the use of a reference sensor 
for a non-organic molecule is paramount. FITC is an ideal choice for the antigen of the reference 
sensor because it typically isn‟t present in biological samples and it doesn‟t simultaneously bind 






Figure 13: QCM-D Setup with Two Sensors in Parallel. The “target sensor” contains antibodies for a 
molecule of interest, whereas the “reference sensor” contains antibodies for a molecule known not to be present 
in the solution. 
 
 
This project investigates the simultaneous incorporation of frequency and dissipation 
changes recorded from QCM-D target and reference sensors in order to infer mass and viscosity 
changes of immunobinding events on a QCM-D biosensor. In an effort to produce clinically-
relevant findings towards designing biosensors for human serum, three antigen environments 
were investigated: a biologically inactive FITC solution, a recombinant bovine serum antigen 
(BSA) solution, and BSA-containing fetal bovine serum (FBS).The first set of experiments 
evaluates FITC as a candidate reference sensor and introduces the concept of antibody stiffening. 
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Next, a pure recombinant protein solution of BSA in PBS was detected with the parallel 
target/reference QCM approach. Fetal bovine serum diluted to the same concentration as the 
prior recombinant BSA solution was detected in order to demonstrate the approach‟s 
effectiveness in complex media. The next set of experiments was carried out to create a dose-
response curve with the BSA in FBS. With these proof-of-concept experiments completed, 
human serum was utilized with the aforementioned biomarkers in order to detect biomarkers 
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2. Antibody Immobilization with QCM-D 
2.1 Antibody Immobilization on the Biosensor 
To clean the gold QCM-D sensors before use, they were first treated with UV/Ozone for 
10 minutes. The sensors were then submerged in a 1:1:5 solution of NH3:H2O2:H2O at 75 ⁰C for 
5 minutes. After being rinsed with distilled water and air dried with nitrogen gas, the sensors 
were again treated with UV/Ozone for 10 minutes. The sensors were then mounted into 
individual flow chambers in the QSense E4 Flow Module system. In order to immobilize 
antibodies onto the surface of the QCM-D, a self-assembled monolayer (SAM) of alkane-thiols 
were created according to the reaction described in 1991.
42
 The SAM and subsequent antibody 
reaction is depicted in Figure 14. 
 
 
Figure 14:Antibody Immobilization Reaction. Alkanethiol bonds mount carbon chains to the gold sensor surface 




When transferring the antibody immobilization reaction protocol to the QCM-D, each 
reaction step in Figure 14 was implemented in three stages: buffer solution flowing at 100 
µL/min, chemical solution in buffer flowing at 100 µL/min, and finally flowing buffer solution 
again. To adsorb the alkanethiol onto the sensor, ethanol was supplied before and after a solution 
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of 0.01 M 3,3'-Dithiodipropionic acid (3,3‟-DTP) in ethanol. Distilled water and air were then 
applied through the chambers for 2 minutes each to wash the surface. Next, 0.655 g of 1-ethyl-3-
(3-dimethylamino-propyl) carbodiimide (EDC) was dissolved in 5.0 mL of 1x Tris-Acetate-
EDTA (TAE buffer) and added to a solution containing 0.765 g N-Hydroxysuccinimide (NHS) 
in 5 mL TAE to afford a 10.0 mL solution of EDC/NHS in TAE. To activate the carboxylic acid, 
the EDC/NHS solution was supplied to the flow chambers with TAE buffer flowing before and 
after. Water and air were once again used to wash the surface.  
Phosphate-buffered saline (PBS) was then applied over each sensor and the flow was 
halted to allow for a static reading of PBS over each sensor. Mouse monoclonal IgG antibodies 
(20 µg/µL PBS) were then supplied to each sensor and allowed to adhere in a non-flowing 
manner to conserve stock antibody solution. For the target sensors, antibodies for the target 
antigen of interest were used. Likewise, for the reference sensor, the reference antibody was 
used. PBS was then flowed over the sensors and paused to obtain a final reading of frequency 
and dissipation. Ethanolamine (0.1 M) was used to block reactive sites which may have been 
inaccessible to the antibodies. Finally, in a similar volume-conserving fashion as that of the 
antibody solution, the test solutions, which contained target antigen, were flowed onto each 
sensor and allowed to rest, before and after their respective phosphate-buffered saline (PBS) 
buffer. The frequency and dissipation output of a typical reaction is shown in Figure 15. 
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Figure 15:  Antibody Immobilization on QCM-D. Antibodies inoculated to the surface of the QCM are used to 
detect binding events indicative of a target molecule. 
 
2.2 Optimizing Antibody Concentration 
 Prior literature inoculates the sensors with 20 µg/mL antibody solution.33,37 Because the 
QSense QCM-D flow chamber requires a minimum solution volume of 140 µL per sensor, 
investigations were carried out to determine if a lower concentration of antibody could be used 
with the same level of inoculation. Antibody solutions of 1 µg/mL, 5 µg/mL, 10µg/mL, and 20 
µg/mL were utilized after the carboxylic activation step and the mass deposition was fairly 
correlative with the antibody concentration (Figure 16). Ultimately, the decision was made to use 
antibody solutions at the same concentration as prior literature (20 µg/mL). 
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Figure 16:  Antibody Deposition vs. Concentration. Antibodies inoculated to the surface of the QCM at different 
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3. Immunospecific Detection of Target Molecules 
3.1 Inorganic Molecules in Saline 
FITC has previously been used as a reference sensor in complex biological media.
37
 The 
Saurbery equation (Equation 4) predicts that binding of the 389.4 Da FITC antigen onto the 150 
kDaIgG αFITC antibody should elicit a slightly negative frequency shift. However, the 
immunobinding event actually induces a dramatically positive frequency shift in a dose-
dependent fashion (Figure 17). Extraction of ultimate mass loading data from these observed 
frequency recordings cannot be directly inferred with the Sauerbrey equation because the biofilm 





Figure 17:  FITC Binding onto QCM-D Biosensor. The positive frequency shift elicited by the FITC – αFITC 
immunoreaction displays a dose-dependent response 
 
 
In order to mathematically incorporate the antibody biofilm layer into the QCM model, 
Hunt et al. developed a partial differential equation which incorporates the stiffness change of 
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the QCM as a result of an immunobinding event with a target antigen (Equation 6).The data 
presented in Figure 17 fit this model; FITC concentration induces increases in frequency shift in 
a dose-dependent fashion.It has previously been reported that antibodies increase their stiffness 
after an immunobinding event.
43
 Because of the miniscule size of FITC in comparison to the 
antibody, the measured increase in frequency shift must be due, in part, to the stiffness change.  
 
 
Figure 18: QCM-D Immunosensor Model. The known biofilm layer in the hf region acts as a spring. Binding of 
antigen to antibody changes the biofilm‟s resonant frequency, ultimately affecting the frequency of the BAW. 
 
3.2 Serum Proteins in Recombinant Solution 
In order to investigate towards clinically relevant findings, several biological media were 
utilized for protein detection. Bovine serum albumin (BSA) is a highly concentrated protein in 
fetal bovine serum (FBS). The first biological experiment was an investigation of recombinant 
BSA protein in PBS buffer. A parallel-flow QCM-D approach was utilized, with αBSA 
antibodies on the target sensor and αFITC antibodies on the reference sensor. After the formation 
of the SAM and antibody layer, a 1 mg/mL solution of BSA in PBS was then applied to each of 
the sensors and allowed to reach steady state ( Δf < 1 Hz/min). The resulting time-varying 
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frequency shifts of the target and reference sensors are depicted in the top two data series of 
Figure 21.  
The model (Figure 18) represents the two generalized areas where BSA could have 
bound in an experimental situation: the gold surface and the antibodies themselves. Despite the 
fact that there is clearly a drop in frequency for both sensors, the results mirror those of the FITC 
trials in that the difference in frequency shift (Equation 7) is a positive change. Using the 
sensors, it was determined that a 1 mg/mL concentration of BSA elicits a frequency shift of 
3.075917 Hz on the third harmonic. This positive change indicates the change in stiffness term of 
Equation 7 is greater than the mass deposition term. 
 
3.3 Blocking Biosensor Surface of Non-Specific Binding 
 Some publications utilized ethanolamine as a blocking agent, though its efficacy in 
blocking large amounts of nonspecific serum is unknown. A single set of experiments showed 
the extent of non-specific binding of FBS (Figure 19). First depicted is the frequency drop due to 
FBS binding onto the gold sensor surface without any prior treatment; no antibodies or thiol 
chains. The next bar represents FBS binding after αFITC antibodies were inoculated. As 
expected, the FBS bound less because the antibodies presumably took up space on the sensor 
surface and sterically hindered the binding sites. The final bar depicts the same reaction (FBS 
onto αFITC), though an additional step with ethanolamine was supplied to the surface prior to 
FBS treatment. As expected, the ethanolamine prevented FBS binding. However, the fact that the 
non-specific binding is being subtracted out makes this step redundant in the overall scope of the 
experiment. As such, ethanolamine was not used in any subsequent serum experimentation. 
 
© Christopher K. Giardina 2011  29 
 
Figure 19: Blocking the Surface with Ethanolamine. (Left) FBS bound the most when it was presented with a 
fresh sensor. (Center)Anti-FITC antibodies removed some of the binding sites and less FBS bound non-specifically 
to the surface. (Right) Treating the anti-FITC layer with ethanolamine further reduced non-specific FBS binding. 
 
 
3.4 Serum Proteins in Blood Serum 
To determine the extent that a reference sensor can account for all non-specific binding, a 
solution of diluted FBS was analyzed with the αBSA target sensor and αFITC reference sensor 
(Figure 20). The concentration of BSA in FBS is roughly 17 mg/mL, so a 1:20 dilution brings 
the concentration nearly equivocal to that of the recombinant protein solution. Because many 
more proteins bound to the surface of the reference sensor with the diluted FBS trial than the 
recombinant BSA experiments, the frequency drop is much greater. However, the sensors in 
tandem were extremely effective in isolating the antibody stiffness change. In the diluted FBS 
sample, a 1 mg/mL BSA concentration causes a 3.10951 Hz frequency shift. Repeated trials 
showed there was no significant difference in BSA frequency shift, whether from recombinant 
solution or diluted serum. 
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Figure 20: Detection of BSA in Recombinant Solution and FBS. Realtime frequency shifts of the third harmonic 
due to adsorption of BSA onto target and reference sensors. At time = 0, the BSA-containing solution (either 
recombinant BSA or FBS) was introduced to the two sets of sensors. At t = 0.9, buffer was introduced. In the case of 
BSA and 1:20 FBS, the changes in viscosity were not noticeable with the addition of buffer. However, there was a 
large frequency shift in the case of pure FBS. 
 
To make use of these data in a diagnostic setting, it would be useful to determine if the 
frequency shift of a 1:20 dilution of FBS was merely 1/20
th
 of the frequency shift of a pure 
sample of FBS. To investigate the ability to extrapolate sensor frequency shifts to other 
concentrations, a pure solution of FBS was analyzed for BSA content in the same fashion as 
before; αFITC reference sensor and αBSA target sensor. Although the recorded antibody 
frequency shift (49.8134 Hz) was within an order of magnitude of the theoretical multiple of 
diluted FBS frequency shift (3.10951 Hz × 20 = 62.1902 Hz), experimentation only yielded a 
frequency shift of 80.098% magnitude. A summary of frequency shifts from the various 
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environments is compiled in Figure 22. There are a number of reasons why the extrapolation was 
not more coincident. Namely, the system is not linear.  
Until now, the assumption has been made that specific and non-specific frequency 
changes are independent of one another. In actuality, this can neither be confirmed nor refuted. 
Possible energy loss due to viscoelastic friction may contribute to nonlinear behavior, and 
interfacial slippage may affect frequency shift.
44
  Additionally, it is currently impossible to 
measure both frequency and stiffness changes independently in order to infer deposition mass 
with Hunt‟s steady state time perturbation equation. Unlike traditional QCM devices, the QCM-
D introduces a roundabout way of evaluating changes in stiffness: viscoelasticity modeling. 
 
3.5 QCM-D Viscoelasticity 
The QSense QCM-D E4 Flow Module was utilized in all experimentation because it can 
simultaneously measure frequency (Equation 4) and dissipation (Equation 10) changes in order 
to infer mass and viscosity changes at the surface of the sensor. As previously mentioned, it is 
necessary to flow a buffer solution before and after a solution which contains a compound which 
will augment the surface of the QCM-D. For example, the first step in the SAM construction is 
the deposition of 3,3‟-DTP (Figure 14). This slight –3.5 Hz frequency shift correlates to 50.0 ng 
of mass added to the surface of the sensor, in the form of ~ 2.86 × 10
14
 alkane-thiol chains. It is 
assumed that the IgG antibody is 5.9 nm × 13.1 nm × 14.3 nm, with a molecular mass of 150 
kDa.
45
 These measurements, along with chemical properties of the known biofilm (Figure 21), 
were incorporated into the viscoelastic models within QSense‟s software in order to conduct 
viscoelasticity measurements. 
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Molecule Molecular Mass Base Area (nm
2
) Height (nm) Density (ng/nm
3
) 
IgG 150 kDa 77.29 14.3 225.443 × 10
-13
 
Au-SAM 98.10 Da 0.04206 0.9057 4.27 × 10 
-12
 
Au-SAM-IgG 150 kDa 77.29 15.2 225.443 × 10
-13
 
Figure 21: Biofilm Properties. Mass, area, height, and density were calculated from known bond lengths and 
assumptions from the biofilm model (Figure 19). 
 
 
Figure 22:Frequency Shifts due to BSA Binding. The 1:20 dilution of FBS contains the same concentration of 
BSA as the recombinant BSA solution. Because the dilution factor (1:20) does not match the multiple difference in 
frequency (15.9), the system is relatively non-linear. 
 
 
The QSense QCM-D software utilizes multiple simultaneous harmonics in its Voight 
viscoelastic model to correct for errors in the Saurbrey model and even to determine viscoelastic 
properties as well. The known chemical structure of the biofilm (Figure 18) was utilized to 
calculate a series of parameters (Figure 21) for use in the viscoelasticity model in the QSense 
QTools program. The recombinant BSA solution, 1:20 FBS dilution, and pure FBS solutions 
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which were previously analyzed for frequency shifts were also used to infer changes in surface 
viscoelasticity. In concordance with the isolation of specific antibody changes, the change in 
reference sensor viscoelasticity was subtracted from the target sensor viscoelasticity (Figure 23). 
Unlike the frequency normalization, the viscoelastic model is much more sensitive to mass 
accumulation at the surface than is the mere frequency shift. At present, this viscoelasticity fits a 




Figure 23:Viscoelasticity Shifts due to BSA Binding. The 1:20 dilution of FBS contains the same concentration of 
BSA as the recombinant BSA solution, yet all chemical environments were shown to have statistically different 
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4. Detection of Recurrence Biomarkers in Human Serum 
 
Patient serum was acquired from the Emory University Serum Bank in 150 µL aliquots 
and 2 cohorts: recurrent prostate cancer and non-recurrent prostate cancer (Figure 24). All ten 
patients had their blood drawn after a successful chemotherapy. Next, the serum was placed in a 
-80 ºC freezer. Four years later, serum was stratified based on whether the patients had 





CFC# TID # of vials 
 
CFC# TID # of vials 
281 2755 7 
 
23 4316 10 
14 4254 5 
 
20 SB 780 7 
218 415 3 
 
16 4289 6 
114 1824 3 
 
22 4330 5 
254 10251 3 
 
12 4291 4 
 
Figure 24: Human Serum Identification. Human serum was acquired in 150 µL aliquots. 5 samples were taken 
from patients with recurrent prostate cancer, and 5 were taken from patients with non-recurrent prostate cancer. 
 
 Sample number 14, from the recurrent cohort, was analyzed on the QCM-D biosensor. 
One sensor had a reference antibody (αFITC), whereas the remaining 3 sensors contained 
antibodies for SIM2, ALP, and PSA (Figure 7). The differences in frequency drops due to the 
various antibodies was negligable, meaning that an approximately equivalent amount of IgG 
antibody bound to each sensor. Once the sensors had their respective antibodies, a 1:10 diluted 
sample of Human Serum #14 (diluted in PBS) was introduced to each sensor (Figure 25). As 
expected, the anti-FITC reference sensor had the greatest drop in frequency. SIM2 and ALP had 
slight increases in frequency due to antibody stiffening, and PSA had a much higher detection.  
Aside from the mere difference in frequency before and after the serum sample, an 
interesting point is the slope of each graph. A steep drop is equivalent to faster binding kinetics: 
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the greater the binding per unit of time. The most overwhelming example of this is the PSA; the 
antibodies for PSA grabbed the PSA in the sample within minutes and was almost immediately 
at steady state. A more gradual binding curve is indicative of non-specific binding because the 
reaction relies on nonspecific binding patterns. The non-specific binding of serum proteins onto 
the αFITC reference sensor in Figure 26 resembles the non-specific binding of antibodies onto 
the alkane-thiol layer during antibody immobilization (Figure 15). A steep curve is likely 
indicative of immunobinding events. 
 
Figure 25: Detection of Recurrent Biomarkers in Human Serum. Diluted human serum sample 14 was presented 
onto four QCM-D immunosensors inoculated with antibodies for FITC, SIM2, ALP, and PSA. As expected, the 
FITC drop was the greatest. Interestingly, the PSA drop was extremely steep, indicating rapid immunobinding 
kinetics unlike the slow binding pattern of non-specific binding onto the surface. 
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 Sample 281, like sample 14, is from the „recurrent‟ cancer cohort. To investigate the 
difference between samples from the same group, the experiment was repeated for sample 281. 
Subtracting the frequency shift due to the reference sensor allowed for the comparison of 
biomarker levels at the antibody (Figure 26). Interestingly, SIM2 levels were extremely similar. 
These experiments will surely be repeated for all serum in Figure 24. 
 
 
Figure 26:Biomarker Levels in Recurrent Prostate Cancer. Diluted human serum sampleswere placed onto 
QCM-D immunosensors inoculated with antibodies for FITC, SIM2, ALP, and PSA. The FITC frequency shift was 
subtracted in order to isolate frequency shift due solely to the biomarker of interest. 
 
QCM-D biosensors were constructed and utilized in a two-sensor approach to isolate 
frequency, dissipation, and viscoelasticity changes while antigens adsorbed onto the surface. The 
reference sensor normalizes for all non-specific protein binding at the surface of the sensor, 
while the target sensor additionally incorporates changes in surface chemistry due to the 
immunobinding event. The uniquely positive frequency shift of FITC binding to its antibody lead 
© Christopher K. Giardina 2011  37 
to the incorporation of mass and stiffness into the Sauerbrey frequency shift model for a series of 
BSA detection experiments in both recombinant protein and FBS solutions.  
These studies showed the best designs to utilize QCM-D biosensors in a clinical 
environment with repeatable results incorporate parallel target and reference sensors which can 
infer a difference in frequency shift. The proof-of-concept testing with various inorganic, 
organic, and complex media allowed for the construction of a sophisticated biosensor capable of 
detecting various biological proteins in human serum. Repeated trials will surely indicate 
whether SIM2 is capable of differentiating between recurrent and non-recurrent prostate cancer 
serum samples. The majority of this work, however, is independent of the biomarker itself. These 
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APPENDIX: QCM-D Protocol 
1. Clean Sensors 
a. Place 4 sensors in the UV-Ozone Chamber for 10 minutes 
b. While in the chamber, make a solution of 5:1:1 H2O:H2O2:NH3and place the 
beaker on a hot plate at 75 ºC 
c. Once the sensors are done in the chamber, use the tweezers to pick up each sensor 
and place it into the plastic holder 
d. Place the holder into the water/ammonia/peroxide solution for 5 minutes 
e. Remove the holder from the solution and rinse with DI water and use N2 to dry 
the sensors 
f. Once dry, remove from holder and place in UV/Ozone again for 10 minutes 
g. Use tweezers to place sensors back in holder and carry to QCM-D 
 
2. Place Sensors in QCM-D Flow Chambers 
a. Flip each sensor chamber upside down and twist off the covers 
b. Use the tweezers to individually load the sensors into each chamber 
c. Twist on each cover, flip over the chamber into its place, and use lever to lock in 
d. Turn on QSense QCM-D machine 
 
3. Calibrate the Sensors 
a. Begin flowing ethanol (EtOH) at 100 µL/min (0.100 on pump) 
b. Once EtOH has hit each chamber, open “QSoft” software 
c. Click on “Setup Acquisition” 
d. Make sure that “all 4 sensors have same resonant frequency” and “Low Noise” 
are selected 
e. Click “Find All” and wait a few minutes for the device to acquire baseline 
resonant frequencies 
f. Next, click “Begin Acquisition” 
g. Wait 2 minutes. Sometimes, the frequencies (blue) or dissipations (red) will vary 
with time, trending up or down. Obviously there‟s nothing going on at the surface, 
so you must recalibrate. Click “stop acquisition” and repeat from step 3C. 
 
4. Immobilizing the Antibodies 
a. With Ethanol still flowing, hit “stop” on the pump and place the inlet tubes into a 
vial of the “3,3‟-DTP in EtOH” and begin suction. MAKE SURE THERE ARE 
NO AIR BUBBLES. 
b. Once the frequency stabilizes (~10 minutes), begin to flow ethanol again to attain 
a final frequency reading. 
c. Next, flow TAE buffer and wait for it to stabilize 
d. Create the NHS/ECD in TAE solution. The NHS is pre-made, but the ECD must 
be made fresh each test. Retrieve the EDC container from the -80 ºC freezer and 
measure the solid. Add TAE, mix well, and add NHS. Once the frequency from 
the TAE is stabilized, flow the NHS/ECD in TAE solution 
e. Once stabilized, flow TAE again. 
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f. Next, flow PBS 
g. Create antibody solutions by performing 1:10 dilutions and 1:20 dilutions of stock 
antibody solutions (marked on paper). 
h. Next, add the antibody solutions individually and let the 140 µL rest on the 
sensor; stop flow once the solution fully enters the chamber. 
i. Perform this for the other 3 sensors; each with its own antibody. 
j. Wait ~45 minutes 
k. Flow PBS on all sensors. At this point, each sensor has the antibody-alkane-thiol 
chain bound to its surface 
 
5. Addition of antigen-containing solution (serum, etc) 
a. Once PBS is stabilized, individually add serum (or whatever else) in the exact 
same fashion as the antibody; one at a time and carefully 
b. Once serum is resting on each sensor, wait ~20 minutes for binding. Make sure to 
completely let the system rest until the final resonant frequency is found. 




a. Save all data 
b. Flow water for a few minutes (can do up to 200 µL/min to save time) 
c. Flow the hellmanex solution 
d. Flow water again 
e. Flow air briefly to remove all liquid from tubing 
f. Turn off pump and unclick each plastic holder on pump (no pressure on tubes) 
g. Turn off QSense Machine 
h. Flip over each chamber, twist off covers, and use tweezers to place sensors in the 
plastic holder 
i. Rinse sensors with methanol, then water, then dry with N2 
j. Store sensors and clean up everything else 
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